Phenotypic characterisation of pro-inflammatory monocytes and dendritic cells in peripheral arterial disease

Thrombosis and Haemostasis

Volumn 108, Issue 6, 2012, Pages 1198-1207

  Dopheide, Jörn F ^a   Obst, Viviane ^a   Doppler, Christopher ^a   Radmacher, Marie Christine ^a   Scheer, Martin ^a   Radsak, Markus P ^a   Gori, Tommaso ^a   Warnholtz, Ascan ^a   Fottner, Christian ^a   Daiber, Andreas ^a   Münzel, Thomas ^a   Espinola Klein, Christine ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Dendritic cells; Inflammation; Monocytes; Peripheral arterial disease

Indexed keywords

C REACTIVE PROTEIN; CD14 ANTIGEN; CD16 ANTIGEN; CD40 ANTIGEN; CD86 ANTIGEN;

AGED; ARTICLE; CELL COUNT; CONTROLLED STUDY; DENDRITIC CELL; DISEASE ASSOCIATION; FEMALE; FLOW CYTOMETRY; HUMAN; INFLAMMATION; ISCHEMIA; MAJOR CLINICAL STUDY; MALE; MONOCYTE; MORPHOLOGICAL TRAIT; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; ANTIGENS, CD40; ANTIGENS, CD86; BLOOD CELL COUNT; CASE-CONTROL STUDIES; DENDRITIC CELLS; EXTREMITIES; FEMALE; HLA-DR ANTIGENS; HUMANS; IMMUNOPHENOTYPING; INFLAMMATION MEDIATORS; INTERMITTENT CLAUDICATION; ISCHEMIA; MALE; MIDDLE AGED; MONOCYTES; PERIPHERAL ARTERIAL DISEASE;

EID: 84871464996     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH12-05-0327     Document Type: Article

References (49)

1. Norgren L, Hiatt WR, Dormandy JA, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg 2007; 33 (Suppl 1): S1-75.
2. Bhatt DL, Steg PG, Ohman EM, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. J Am Med Assoc 2006; 295: 180-189.
3. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999; 340: 115-126.
4. Hansson GK, Libby P, Schönbeck U, et al. Innate and Adaptive Immunity in the Pathogenesis of Atherosclerosis. Circ Res 2002; 91: 281-291.
5. Weber C, Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat Med 2011; 17: 1410-1422.
6. Ni K, O'Neill HC. The role of dendritic cells in T-cell activation. Immunol Cell Biol 1997; 75: 223-230.
7. Ziegler-Heitbrock L, Ancuta P, Crowe S, et al. Nomenclature of monocytes and dendritic cells in blood. Blood 2010; 116: e74-80.
8. Belge KU, Dayyani F, Horelt A, et al. The proinflammatory CD14+CD16+DR++ monocytes are a major source of TNF. J Immunol 2002; 168: 3536-3542.
9. Schlitt A, Heine G, Blankenberg S, et al. CD14+CD16+ Monocytes are a Risk factor for Coronary Artery Disease and related to Serum TNF-a-levels. Thromb Haemost 2004; 92: 419-424.
10. Hristov M, Leyendecker T, Schuhmann C, et al. Circulating monocyte subsets and cardiovascular risk factors in coronary artery disease. Thromb Haemost 2010; 104: 412-414.
11. Bobryshev YV, Lord RSA. S-100 positive cells in human arterial intima and in atherosclerotic lesions. Cardiovasc Res 1995; 29: 689-696.
12. Yilmaz A, Lochno M, Traeg F, et al. Emergence of dendritic cells in rupture-prone regions of vulnerable carotid plaques. Atherosclerosis 2004 Sep; 176: 101-110.
13. Niessner A, Sato K, Chaikof EL, et al. Pathogen-sensing plasmacytoid dendritic cells stimulate cytotoxic T-cell function in the atherosclerotic plaque through interferon-alpha. Circulation 2006; 114: 2482-2489.
14. Yilmaz A, Weber J, Cicha I, et al. Decrease in Circulating Myeloid Dendritic Cell Precursors in Coronary Artery Disease. J Am Coll Cardiol 2006; 48: 70-80.
15. Van Vre EA, Hoymans VY, Bult H, et al. Decreased number of circulating plasmacytoid dendritic cells in patients with atherosclerotic coronary artery disease. Coron Artery Dis 2006; 17: 243-248.
16. Shortman K, Naik SH. Steady-state and inflammatory dendritic-cell development. Nat Rev Immunol 2007; 7: 19-30.
17. Shimada K. Immune system and atherosclerotic disease: heterogeneity of leukocyte subsets participating in the pathogenesis of atherosclerosis. Circ J 2009; 73: 994-1001.
18. Randolph GJ, Ochando J, Partida-Sanchez S. Migration of dendritic cell subsets and their precursors. Annu Rev Immunol 2008; 26: 293-316.
19. Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature 2007; 449: 419-426.
20. Matta BM, Castellaneta A, Thomson AW. Tolerogenic plasmacytoid DC. Eur J Immunol 2010; 40: 2667-2676.
21. Della Bella S, Giannelli S, Taddeo A, et al. Application of six-color flow cytometry for the assessment of dendritic cell responses in whole blood assays. J Immunol Methods 2008; 339: 153-164.
22. Borissoff JI, Spronk HM, ten Cate H. The hemostatic system as a modulator of atherosclerosis. N Engl J Med 2011; 364: 1746-1760.
23. Langer HF, Daub K, Braun G, et al. Platelets recruit human dendritic cells via Mac-1/JAM-C interaction and modulate dendritic cell function in vitro. Arterioscler Thromb Vasc Biol 2007; 27: 1463-1470.
24. Bobryshev YV, Lord RSA. Ultrastructural recognition of cells with dendritic cell morphology in human aortic intima. Contacting interactions of Vascular Dendritic Cells in arthero-resistant and arthero-prone areas of the normal aorta. Arch Histol Cytol 1995; 58: 307-322.
25. Millonig G, Niederegger H, Rabl W, et al. Network of Vascular-Associated Dendritic Cells in Intima of Healthy Young Individuals. Arterioscler Thromb Vasc Biol 2001; 21: 503-508.
26. Millonig G, Schwentner C, Mueller P, et al. The vascular-associated lymphoid tissue: a new site of local immunity. Curr Opin Lipidol 2001; 12: 547-553.
27. Belge KU, Dayyani F, Horelt A, et al. The Proinflammatory CD14+CD16+DR++ Monocytes Are a Major Source of TNF. J Immunol 2002; 168: 3536-3542.
28. +blood monocytes exhibits features of tissue macrophages. Eur J Immunol 1993; 23: 2053-2058.
29. Acunta P, Weiss L, Haeffner-Cavaillon N. CD14+CD16++ cells derived in vitro from peripheral blood monocytes exhibit phenotypic and functional dendritic cell-like characteristics. Eur J Immunol 2000; 30: 1872-1883.
30. Randolph GJ, Sanchez-Schmitz G, Liebman RM, et al. The CD16+ (Fc{gamma}RIII+) Subset of Human Monocytes Preferentially Becomes Migratory Dendritic Cells in a Model Tissue Setting. J Exp Med 2002; 196: 517-527.
31. Schakel K, Kannagi R, Kniep B, et al. 6-Sulfo LacNAc, a novel carbohydrate modification of PSGL-1, defines an inflammatory type of human dendritic cells. Immunity 2002; 17: 289-301.
32. de Baey A, Mende I, Riethmueller G, et al. Phenotype and function of human dendritic cells derived from M-DC8+ monocytes. Eur J Immunol 2001; 31: 1646-1655.
33. Ancuta P, Moses A, Gabuzda D. Transendothelial migration of CD16+ monocytes in response to fractalkine under constitutive and inflammatory conditions. Immunobiology 2004; 209: 11-20.
34. Ancuta P, Rao R, Moses A, et al. Fractalkine preferentially mediates arrest and migration of CD16+ monocytes. J Exp Med 2003; 197: 1701-1707.
35. Llodra J, Angeli V, Liu J, et al. Emigration of monocyte-derived cells from atherosclerotic lesions characterizes regressive, but not progressive, plaques. Proc Natl Acad Sci USA 2004; 101: 11779-11784.
36. Berg KE, Ljungcrantz I, Andersson L, et al. Elevated CD14++CD16-monocytes predict cardiovascular events. Circ Cardiovasc Genet 2012; 5: 122-131.
37. Hristov M, Leyendecker T, Schuhmann C, et al. Circulating monocyte subsets and cardiovascular risk factors in coronary artery disease. Thromb Haemost 2010; 104: 412-414.
38. Swirski FK, Libby P, Aikawa E, et al. Ly-6Chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata. J Clin Invest 2007; 117: 195-205.
39. Weber C, Belge KU, von Hundelshausen P, et al. Differential chemokine receptor expression and function in human monocyte subpopulations. J Leukoc Biol 2000; 67: 699-704.
40. Zawada AM, Rogacev KS, Rotter B, et al. SuperSAGE evidence for CD14++CD16+ monocytes as a third monocyte subset. Blood 2011; 118: e50-61.
41. Pucci F, Venneri MA, Biziato D, et al. A distinguishing gene signature shared by tumor-infiltrating Tie2-expressing monocytes, blood "resident" monocytes, and embryonic macrophages suggests common functions and developmental relationships. Blood 2009; 114: 901-914.
42. Hristov M, Schmitz S, Schuhmann C, et al. An optimized flow cytometry protocol for analysis of angiogenic monocytes and endothelial progenitor cells in peripheral blood. Cytometry A 2009; 75: 848-853.
43. Girndt M, Köhler H, Schiedhelm Weick E, et al. T cell activation defect in hemodialysis patients: evidence for a role of the B7/CD28 pathway. Kidney Int 1993; 44: 359-365.
44. Girndt M, Sester U, Sester M, et al. Impaired cellular immune function in patients with end-stage renal failure. Nephrol Dial Transplant 1999; 14: 2807-2810.
45. Daissormont IT, Christ A, Temmerman L, et al. Plasmacytoid dendritic cells protect against atherosclerosis by tuning T-cell proliferation and activity. Circ Res 2011; 109: 1387-1395.
46. Doring Y, Manthey HD, Drechsler M, et al. Auto-antigenic protein-DNA complexes stimulate plasmacytoid dendritic cells to promote atherosclerosis. Circulation 2012; 125: 1673-1683.
47. Niessner A, Weyand CM. Dendritic cells in atherosclerotic disease. Clin Immunol 2010; 134: 25-32.
48. Dzionek A, Fuchs A, Schmidt P, et al. BDCA-2, BDCA-3, and BDCA-4: three markers for distinct subsets of dendritic cells in human peripheral blood. J Immunol 2000; 165: 6037-6046.
49. Rovati B, Mariucci S, Manzoni M, et al. Flow cytometric detection of circulating dendritic cells in healthy subjects. Eur J Histochem 2008; 52: 45-52.